552 related articles for article (PubMed ID: 28133981)
1. Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer's disease.
Wu WY; Dai YC; Li NG; Dong ZX; Gu T; Shi ZH; Xue X; Tang YP; Duan JA
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):572-587. PubMed ID: 28133981
[TBL] [Abstract][Full Text] [Related]
2. Tacrine derivatives and Alzheimer's disease.
Tumiatti V; Minarini A; Bolognesi ML; Milelli A; Rosini M; Melchiorre C
Curr Med Chem; 2010; 17(17):1825-38. PubMed ID: 20345341
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core.
Lin H; Li Q; Gu K; Zhu J; Jiang X; Chen Y; Sun H
Curr Top Med Chem; 2017; 17(27):3000-3016. PubMed ID: 28714419
[TBL] [Abstract][Full Text] [Related]
4. Recent Developments in Tacrine-based Hybrids as a Therapeutic Option for Alzheimer's Disease.
Yamali C; Donmez S
Mini Rev Med Chem; 2023; 23(7):869-880. PubMed ID: 36464869
[TBL] [Abstract][Full Text] [Related]
5. Multi-Target Drug Design of Anti-Alzheimer's Disease based on Tacrine.
Tian S; Huang Z; Meng Q; Liu Z
Mini Rev Med Chem; 2021; 21(15):2039-2064. PubMed ID: 33583371
[TBL] [Abstract][Full Text] [Related]
6. Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment.
Minarini A; Milelli A; Tumiatti V; Rosini M; Simoni E; Bolognesi ML; Andrisano V; Bartolini M; Motori E; Angeloni C; Hrelia S
Neuropharmacology; 2012 Feb; 62(2):997-1003. PubMed ID: 22032870
[TBL] [Abstract][Full Text] [Related]
7. Multitarget Tacrine Hybrids with Neuroprotective Properties to Confront Alzheimer's Disease.
Spilovska K; Korabecny J; Nepovimova E; Dolezal R; Mezeiova E; Soukup O; Kuca K
Curr Top Med Chem; 2017; 17(9):1006-1026. PubMed ID: 27697055
[TBL] [Abstract][Full Text] [Related]
8. Design Synthesis and
Remya RS; Ramalakshmi N; Nalini CN; Niraimathi V; Amuthalakshmi S
Curr Comput Aided Drug Des; 2022; 18(4):271-292. PubMed ID: 35927818
[TBL] [Abstract][Full Text] [Related]
9. Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease.
Jeřábek J; Uliassi E; Guidotti L; Korábečný J; Soukup O; Sepsova V; Hrabinova M; Kuča K; Bartolini M; Peña-Altamira LE; Petralla S; Monti B; Roberti M; Bolognesi ML
Eur J Med Chem; 2017 Feb; 127():250-262. PubMed ID: 28064079
[TBL] [Abstract][Full Text] [Related]
10. A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease.
Sameem B; Saeedi M; Mahdavi M; Shafiee A
Eur J Med Chem; 2017 Mar; 128():332-345. PubMed ID: 27876467
[TBL] [Abstract][Full Text] [Related]
11. Molecular perception of interactions between bis(7)tacrine and cystamine-tacrine dimer with cholinesterases as the promising proposed agents for the treatment of Alzheimer's disease.
Eslami M; Hashemianzadeh SM; Bagherzadeh K; Seyed Sajadi SA
J Biomol Struct Dyn; 2016; 34(4):855-69. PubMed ID: 26043757
[TBL] [Abstract][Full Text] [Related]
12. Dimeric Tacrine(10)-hupyridone as a Multitarget-Directed Ligand To Treat Alzheimer's Disease.
Xuan Z; Gu X; Yan S; Xie Y; Zhou Y; Zhang H; Jin H; Hu S; Mak MSH; Zhou D; Keung Tsim KW; Carlier PR; Han Y; Cui W
ACS Chem Neurosci; 2021 Jul; 12(13):2462-2477. PubMed ID: 34156230
[TBL] [Abstract][Full Text] [Related]
13. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease.
Ismaili L; Refouvelet B; Benchekroun M; Brogi S; Brindisi M; Gemma S; Campiani G; Filipic S; Agbaba D; Esteban G; Unzeta M; Nikolic K; Butini S; Marco-Contelles J
Prog Neurobiol; 2017 Apr; 151():4-34. PubMed ID: 26797191
[TBL] [Abstract][Full Text] [Related]
14. New Multitarget Hybrids Bearing Tacrine and Phenylbenzothiazole Motifs as Potential Drug Candidates for Alzheimer's Disease.
Rajeshwari R; Chand K; Candeias E; Cardoso SM; Chaves S; Santos MA
Molecules; 2019 Feb; 24(3):. PubMed ID: 30736397
[TBL] [Abstract][Full Text] [Related]
15. Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease.
Hiremathad A; Keri RS; Esteves AR; Cardoso SM; Chaves S; Santos MA
Eur J Med Chem; 2018 Mar; 148():255-267. PubMed ID: 29466775
[TBL] [Abstract][Full Text] [Related]
16. Tacrine-Natural-Product Hybrids for Alzheimer's Disease Therapy.
Oset-Gasque MJ; Marco-Contelles JL
Curr Med Chem; 2020; 27(26):4392-4400. PubMed ID: 29611473
[TBL] [Abstract][Full Text] [Related]
17. Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§.
Milelli A; De Simone A; Ticchi N; Chen HH; Betari N; Andrisano V; Tumiatti V
Curr Med Chem; 2017; 24(32):3522-3546. PubMed ID: 28294041
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and neuroprotective evaluation of novel tacrine-benzothiazole hybrids as multi-targeted compounds against Alzheimer's disease.
Keri RS; Quintanova C; Marques SM; Esteves AR; Cardoso SM; Santos MA
Bioorg Med Chem; 2013 Aug; 21(15):4559-69. PubMed ID: 23768661
[TBL] [Abstract][Full Text] [Related]
19. Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.
Camps P; Muñoz-Torrero D
Mini Rev Med Chem; 2001 Jul; 1(2):163-74. PubMed ID: 12369981
[TBL] [Abstract][Full Text] [Related]
20. East meets West in the search for Alzheimer's therapeutics - novel dimeric inhibitors from tacrine and huperzine A.
Li WM; Kan KK; Carlier PR; Pang YP; Han YF
Curr Alzheimer Res; 2007 Sep; 4(4):386-96. PubMed ID: 17908041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
